Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHF 5188
- Development stage
- Phase 2
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
CHF 5188 is an investigational drug that was studied for its bronchodilator effects in patients with moderate or severe asthma. It was evaluated in a clinical trial to determine whether once-daily morning dosing could maintain bronchodilation in this patient population. The specific mechanism of action, molecular target, and chemical class of CHF 5188 are not detailed in the available public sources. The developer associated with this code name is Chiesi Farmaceutici, as indicated by the "CHF" prefix commonly used for their pipeline compounds.
Beyond the preview
Go deeper on CHF 5188.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHF 5188.